Ranitidine HCl Injection bulk supplier for pharma manufacturers

Ranitidine HCl Injection 50mg/2ml Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 50mg/2ml

Reference Brands: Zantac (USA/EU)

Ranitidine 50 mg/2 mL injection, an H2-receptor antagonist for hospital acid suppression. Withdrawn or suspended in several major markets, so it is offered only to licensed importers and hospitals where it remains registered.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ranitidine HCl Injection? List it or send an offer →

Product Description:

Ranitidine is a histamine H2-receptor antagonist. It blocks histamine at the acid-producing parietal cells and reduces both resting and meal-stimulated acid secretion. This page covers the 50 mg/2 mL solution for injection, which hospitals used when patients could not take tablets or needed quick acid suppression, for example around surgery. It can be given intravenously or intramuscularly. Oral ranitidine has left the market in many countries, and the injection faces the same regulatory scrutiny.

Labelled hospital uses included ulcers in patients unable to take oral therapy, stress ulcer prophylaxis in critically ill patients, Zollinger-Ellison syndrome, and cutting the risk of acid aspiration before anaesthesia. The usual adult dose was 50 mg every six to eight hours, intravenously after dilution to 20 mL over at least two minutes, or intramuscularly, with lower doses in severe renal impairment. In 2020 US and EU regulators withdrew or suspended ranitidine medicines after finding NDMA, a probable human carcinogen, in some products.

Sourcing notes. Before any order, confirm that ranitidine injection is still registered and permitted in the destination country, as many authorities have suspended it. Where it remains authorised, ask for the nitrosamine risk assessment and NDMA results for each batch against your regulator's limit, with the certificate of analysis, GMP certificate and CoPP. Stability data should cover NDMA levels across the shelf life, including Zone IVb conditions for hot, humid markets. Ampoules should be protected from light. It is prescription-only. Give ampoules per box and quantity.

Ranitidine HCl Injection — third party manufacturing & bulk supply

Ranitidine HCl Injection 50mg/2ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ranitidine HCl Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ranitidine HCl Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ranitidine HCl Injection →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ranitidine is used to reduce stomach acid production and treat conditions such as gastric ulcers, duodenal ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

Ranitidine is made from Ranitidine Hydrochloride, a compound that blocks histamine H2 receptors in the stomach, thereby reducing acid secretion.

The most common trade name was Zantac, along with Rantac, Aciloc, Histac, and Zinetac in various regions.

Ranitidine was originally developed and marketed under the brand Zantac by GlaxoSmithKline (GSK), with many global and Indian manufacturers producing generic versions.

The generic name is Ranitidine Hydrochloride.

Brand names included Zantac, Rantac, Aciloc, Histac, and Zinetac.

Ranitidine was manufactured globally, including in the USA, Europe, India, and other pharmaceutical manufacturing hubs, though current production depends on regulatory approvals due to safety concerns.